marketcaparena
Search

    CSBR

    CHAMPIONS ONCOLOGY, INC.

    Company overview

    Market capitalization
    $68.62M
    Employees
    213
    Latest publication
    2026-09-29
    About CHAMPIONS ONCOLOGY, INC.

    Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20272026-07-31 · USDQ3 20262026-01-31 · USDQ2 20262025-10-31 · USDQ1 20262025-07-31 · USDQ3 20252025-01-31 · USDQ2 20252024-10-31 · USDQ1 20252024-07-31 · USDQ4 20242024-04-30 · USD
    Total Revenue15,232,000USD16,559,000USD15,035,000USD13,995,000USD17,039,000USD13,489,000USD14,061,000USD14,002,000USD
    Cost Of Revenue7,534,000USD8,834,000USD7,262,000USD7,995,000USD6,617,000USD7,428,000USD7,072,000USD7,250,000USD
    Gross Profit7,698,000USD7,725,000USD7,773,000USD6,000,000USD10,422,000USD6,061,000USD6,989,000USD6,752,000USD
    Research Development2,344,000USD2,271,000USD2,616,000USD2,081,999USD1,719,000USD1,689,000USD1,454,000USD2,049,000USD
    Selling General Administrative2,673,000USD2,975,000USD2,974,000USD2,570,000USD2,398,000USD1,889,000USD2,527,000USD2,762,000USD
    Selling And Marketing Expenses3,090,000USD2,666,000USD1,998,000USD1,855,000USD1,806,000USD1,751,000USD1,679,000USD1,776,000USD
    General And Administrative Expenses2,673,000USD———————
    Total Operating Expenses8,107,000USD7,912,000USD7,588,000USD6,507,000USD5,923,000USD5,329,000USD5,660,000USD7,023,000USD
    Operating Income-409,000USD-187,000USD185,000USD-507,000USD4,499,000USD732,000USD1,329,000USD-271,000USD
    Total Other Income Expense Net-6,000USD-50,000USD70,000USD55,000USD19,000USD7,000USD5,000USD81,000USD
    Income Before Tax-415,000USD-237,000USD255,000USD-452,000USD4,518,000USD739,000USD1,334,000USD-190,000USD
    Income Tax Expense11,000USD42,000USD18,000USD14,000USD23,000USD11,000USD21,000USD-81,000USD
    Net Income-426,000USD-279,000USD299,000USD-466,000USD4,495,000USD728,000USD1,313,000USD-109,000USD
    Tax Provision—42,000USD18,000USD14,000USD23,000USD11,000USD21,000USD-81,000USD
    Net Income From Continuing Ops—-279,000USD237,000USD-466,000USD4,495,000USD728,000USD1,313,000USD-109,000USD
    Ebit—-237,000USD255,000USD-452,000USD4,518,000USD739,000USD1,334,000USD164,000USD
    Ebitda—104,000USD612,000USD-94,000USD4,916,000USD1,138,000USD1,783,000USD621,000USD
    Depreciation And Amortization—341,000USD357,000USD358,000USD398,000USD399,000USD449,000USD457,000USD
    Reconciled Depreciation—341,000USD357,000USD358,000USD398,000USD399,000USD449,000USD457,000USD
    Minority Interest——31,000USD—————
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-04-30 · USDFY 20252025-04-30 · USDFY 20222022-04-30 · USDFY 20212021-04-30 · USDFY 20192019-04-30 · USDFY 20082008-04-30 · USDFY 20072007-04-30 · USDFY 20062006-04-30 · USD
    Total Revenue59,425,000USD56,944,000USD49,109,000USD41,040,000USD27,067,000USD1,400,000USD——
    Cost Of Revenue30,900,000USD28,389,000USD23,632,000USD21,446,000USD14,265,000USD490,000USD——
    Gross Profit28,525,000USD28,555,000USD25,477,000USD19,594,000USD12,802,000USD910,000USD——
    Research Development9,084,000USD6,825,000USD9,374,000USD7,196,000USD4,798,000USD199,743USD——
    Selling And Marketing Expenses9,318,000USD7,545,000USD6,379,000USD5,520,000USD3,056,000USD———
    General And Administrative Expenses11,152,000USD———————
    Total Operating Expenses29,665,000USD23,709,000USD24,870,000USD19,228,000USD12,532,000USD1,350,000USD170,058USD144,117USD
    Operating Income-1,140,000USD4,846,000USD607,000USD366,000USD270,000USD-440,000USD-170,058USD-144,117USD
    Total Other Income Expense Net211,000USD-220,000USD-24,000USD71,000USD-39,000USD29,000USD——
    Income Before Tax-929,000USD4,626,000USD583,000USD437,000USD231,000USD-411,000USD-170,058USD-144,117USD
    Income Tax Expense246,000USD-75,000USD35,000USD75,000USD103,000USD——159,601USD
    Net Income-1,175,000USD4,701,000USD548,000USD362,000USD128,000USD-411,000USD-170,058USD-303,718USD
    Selling General Administrative—9,339,000USD9,117,000USD6,512,000USD4,678,000USD1,193,611USD170,058USD144,117USD
    Interest Expense—27,000USD24,000USD71,000USD39,000USD0USD0USD0USD
    Tax Provision—-75,000USD35,000USD75,000USD103,000USD———
    Net Income From Continuing Ops—4,701,000USD548,000USD334,000USD128,000USD———
    Ebit—4,626,000USD583,000USD366,000USD270,000USD-610,127USD-170,058USD-144,117USD
    Ebitda—6,266,000USD2,210,000USD1,550,000USD876,000USD-440,000USD-159,012USD-144,117USD
    Depreciation And Amortization—1,640,000USD1,627,000USD1,184,000USD606,000USD170,127USD11,046USD—
    Reconciled Depreciation—1,640,000USD1,627,000USD1,184,000USD606,000USD———
    Non Operating Income Net Other——-24,000USD71,000USD-39,000USD———
    Net Income Applicable To Common Shares——548,000USD362,000USD128,000USD———
    Other Operating Expenses——————170,058USD144,117USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20272026-07-31 · USDQ4 20262026-04-30 · USDQ3 20262026-01-31 · USDQ2 20262025-10-31 · USDQ1 20262025-07-31 · USDQ4 20252025-04-30 · USDQ3 20252025-01-31 · USDQ2 20252024-10-31 · USD
    Total Assets33,290,000USD26,989,000USD28,447,000USD30,162,000USD30,546,000USD32,344,000USD30,627,000USD25,240,000USD
    Cash And Equivalents4,358,000USD———————
    Total Current Assets19,292,000USD19,219,000USD20,185,000USD21,332,000USD21,014,000USD22,369,000USD19,697,000USD14,084,000USD
    Other Current Assets1,332,000USD1,169,000USD991,000USD1,277,000USD1,215,000USD1,350,000USD713,000USD860,000USD
    Other Non Current Assets201,000USD212,000USD——————
    Total Liabilities28,830,000USD22,921,000USD——————
    Total Current Liabilities18,729,000USD19,922,000USD20,677,000USD22,141,000USD22,698,000USD23,853,000USD19,870,000USD18,861,000USD
    Other Current Liabilities234,000USD79,000USD——————
    Other Non Current Liabilities215,000USD7,000USD——————
    Total Stockholder Equity3,893,000USD3,939,000USD4,283,000USD4,170,000USD3,508,000USD3,772,000USD5,469,000USD681,000USD
    Total Equity Including Noncontrolling Interest4,460,000USD4,068,000USD——————
    Deferred Revenue9,552,000USD8,828,000USD——————
    Net Receivables13,602,000USD13,178,000USD12,067,000USD11,539,000USD9,474,000USD11,234,000USD15,782,000USD10,470,000USD
    Property Plant Equipment Net13,462,000USD7,223,000USD9,260,000USD8,299,000USD9,001,000USD9,455,000USD10,410,000USD10,636,000USD
    Goodwill335,000USD335,000USD——————
    Accounts Payable5,632,000USD6,903,000USD5,726,000USD5,993,000USD4,845,000USD4,248,000USD5,093,000USD4,854,000USD
    Short Term Debt635,000USD1,520,000USD1,607,000USD1,525,000USD1,506,000USD1,471,000USD1,434,000USD1,401,000USD
    Common Stock14,000USD14,000USD14,000USD14,000USD14,000USD14,000USD14,000USD14,000USD
    Retained Earnings-81,493,000USD-81,067,000USD-80,400,000USD-80,121,000USD-80,358,000USD-79,892,000USD-78,057,000USD-82,552,000USD
    Total Liab——24,069,000USD25,931,000USD27,008,000USD28,572,000USD25,158,000USD24,559,000USD
    Other Current Liab——3,346,000USD2,285,000USD1,917,000USD2,691,000USD2,421,000USD2,386,000USD
    Capital Stock——14,000USD14,000USD14,000USD14,000USD14,000USD14,000USD
    Good Will——335,000USD335,000USD335,000USD335,000USD335,000USD335,000USD
    Cash——7,127,000USD8,516,000USD10,325,000USD9,785,000USD3,202,000USD2,754,000USD
    Cash And Short Term Investments——7,127,000USD8,516,000USD10,325,000USD9,785,000USD3,202,000USD2,754,000USD
    Current Deferred Revenue——9,998,000USD12,338,000USD14,430,000USD15,443,000USD10,922,000USD10,220,000USD
    Net Debt——-2,128,000USD-3,247,000USD-4,575,000USD-3,680,000USD3,235,000USD4,021,000USD
    Short Long Term Debt Total——4,999,000USD5,269,000USD5,750,000USD6,105,000USD6,437,000USD6,775,000USD
    Property Plant Equipment Gross——20,207,000USD20,678,000USD21,023,000USD21,143,000USD22,046,000USD21,875,000USD
    Common Stock Shares Outstanding——13,886,797shares14,457,837shares13,788,414shares13,753,575shares14,364,904shares14,016,953shares
    Non Current Assets Total——8,262,000USD8,830,000USD9,532,000USD9,975,000USD10,930,000USD11,156,000USD
    Non Current Liabilities Total——3,392,000USD3,790,000USD4,310,000USD4,719,000USD5,288,000USD5,698,000USD
    Non Current Liabilities Other——27,000USD46,000USD66,000USD85,000USD285,000USD324,000USD
    Non Currrent Assets Other——-1,333,000USD196,000USD196,000USD185,000USD185,000USD185,000USD
    Net Working Capital——-492,000USD-809,000USD-1,684,000USD-1,484,000USD-173,000USD-4,777,000USD
    Unclassified Non Current Assets——-1,333,000USD—————
    Unclassified Non Current Liabilities——3,365,000USD3,744,000USD4,244,000USD4,634,000USD5,003,000USD5,374,000USD
    Unclassified Equity——84,655,000USD84,263,000USD83,838,000USD83,636,000USD83,498,000USD83,205,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-04-30 · USDFY 20252025-04-30 · USDFY 20242024-04-30 · USDFY 20232023-04-30 · USDFY 20222022-04-30 · USDFY 20212021-04-30 · USDFY 20202020-04-30 · USDFY 20192019-04-30 · USD
    Total Assets26,989,000USD32,344,000USD26,132,000USD34,311,000USD35,378,000USD27,591,000USD20,751,000USD11,265,000USD
    Total Current Assets19,219,000USD22,369,000USD13,639,000USD19,457,000USD19,664,000USD12,630,000USD13,497,000USD7,922,000USD
    Other Current Assets1,169,000USD1,350,000USD1,495,000USD1,328,000USD1,144,000USD957,000USD385,000USD308,000USD
    Other Non Current Assets212,000USD———————
    Total Liabilities22,921,000USD———————
    Total Current Liabilities19,922,000USD23,853,000USD21,541,000USD21,733,000USD17,479,000USD11,199,000USD12,304,000USD8,025,000USD
    Other Current Liabilities79,000USD———————
    Other Non Current Liabilities7,000USD———————
    Total Stockholder Equity3,939,000USD3,772,000USD-1,903,000USD4,636,000USD9,096,000USD7,428,000USD5,099,000USD2,238,000USD
    Total Equity Including Noncontrolling Interest4,068,000USD———————
    Deferred Revenue8,828,000USD———————
    Net Receivables13,178,000USD11,234,000USD9,526,000USD8,011,000USD9,513,000USD6,986,000USD4,770,000USD4,377,000USD
    Property Plant Equipment Net7,223,000USD9,455,000USD11,973,000USD14,504,000USD15,364,000USD14,611,000USD6,791,000USD2,546,000USD
    Goodwill335,000USD———————
    Accounts Payable6,903,000USD4,248,000USD5,800,000USD5,334,000USD2,868,000USD1,894,000USD3,140,000USD2,807,000USD
    Short Term Debt1,520,000USD1,471,000USD1,337,000USD1,208,000USD1,054,000USD818,000USD628,000USD16,000USD
    Common Stock14,000USD14,000USD14,000USD14,000USD14,000USD13,000USD13,000USD12,000USD
    Retained Earnings-81,067,000USD-79,892,000USD-84,593,000USD-77,317,000USD-71,982,000USD-72,530,000USD-72,892,000USD-70,698,000USD
    Total Liab—28,572,000USD28,035,000USD29,675,000USD26,282,000USD20,163,000USD15,652,000USD9,027,000USD
    Other Current Liab—2,691,000USD2,310,000USD2,415,000USD2,486,000USD2,231,000USD2,700,000USD1,180,000USD
    Capital Stock—14,000USD14,000USD14,000USD14,000USD13,000USD13,000USD12,000USD
    Good Will—335,000USD335,000USD335,000USD335,000USD335,000USD335,000USD669,000USD
    Cash—9,785,000USD2,618,000USD10,118,000USD9,007,000USD4,687,000USD8,342,000USD3,237,000USD
    Cash And Short Term Investments—9,785,000USD2,618,000USD10,118,000USD9,007,000USD4,687,000USD8,342,000USD3,237,000USD
    Current Deferred Revenue—15,443,000USD12,094,000USD12,776,000USD11,071,000USD6,256,000USD5,815,000USD4,022,000USD
    Net Debt—-3,680,000USD4,812,000USD-1,519,000USD459,000USD4,914,000USD-4,544,000USD-3,221,000USD
    Short Long Term Debt Total—6,105,000USD7,430,000USD8,599,000USD9,466,000USD9,601,000USD3,798,000USD16,000USD
    Property Plant Equipment Gross—21,143,000USD22,364,000USD14,504,000USD15,364,000USD14,611,000USD6,791,000USD2,546,000USD
    Common Stock Shares Outstanding—14,266,781shares13,547,604shares13,541,559shares14,159,799shares14,573,561shares11,843,463shares14,096,117shares
    Non Current Assets Total—9,975,000USD12,493,000USD14,854,000USD15,714,000USD14,961,000USD7,254,000USD3,343,000USD
    Non Current Liabilities Total—4,719,000USD6,494,000USD7,942,000USD8,803,000USD8,964,000USD3,348,000USD1,002,000USD
    Non Current Liabilities Other—85,000USD401,000USD7,942,000USD8,803,000USD181,000USD178,000USD1,002,000USD
    Non Currrent Assets Other—185,000USD185,000USD15,000USD15,000USD15,000USD128,000USD128,000USD
    Net Working Capital—-1,484,000USD-7,902,000USD-2,276,000USD2,185,000USD1,431,000USD1,412,000USD-103,000USD
    Unclassified Non Current Liabilities—4,634,000USD6,093,000USD——8,602,000USD2,992,000USD-1,853,000USD
    Unclassified Equity—83,636,000USD82,662,000USD81,925,000USD81,050,000USD79,932,000USD80,737,000USD72,912,000USD
    Inventory——1USD1USD——1USD1USD
    Accumulated Other Comprehensive Income——0USD0USD—0USD-2,772,000USD0USD
    Other Liab———551,000USD391,000USD181,000USD178,000USD1,002,000USD
    Other Assets———15,000USD15,000USD15,000USD128,000USD128,000USD
    Net Tangible Assets———4,301,000USD8,761,000USD7,093,000USD4,983,000USD1,569,000USD
    Deferred Long Term Liab———————851,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20272026-07-31 · USDQ3 20262026-01-31 · USDQ2 20262025-10-31 · USDQ1 20262025-07-31 · USDQ4 20252025-04-30 · USDQ3 20252025-01-31 · USDQ2 20252024-10-31 · USDQ1 20252024-07-31 · USD
    Depreciation314,000USD341,000USD357,000USD358,000USD394,000USD398,000USD399,000USD449,000USD
    Stock Based Compensation766,000USD423,000USD249,000USD208,000USD131,000USD256,000USD9,000USD258,000USD
    Change To Account Receivables-414,000USD319,000USD-2,078,000USD1,759,000USD4,500,000USD-5,272,000USD-1,229,000USD565,000USD
    Change To Liabilities-1,342,000USD———————
    Change In Working Capital-1,991,000USD2,806,000USD-3,005,000USD199,000USD7,727,000USD-4,917,000USD-1,504,000USD-1,927,000USD
    Operating Cash Flow-492,000USD———————
    Capital Expenditures-55,000USD-37,000USD-242,000USD-46,000USD-253,000USD-42,000USD-94,000USD0USD
    Investing Cash Flow-55,000USD———————
    Net Debt Issuance-19,000USD———————
    Unclassified Financing Cash Flow52,000USD———————
    Financing Cash Flow33,000USD———————
    Change In Cash-514,000USD-1,389,000USD-1,809,000USD540,000USD6,583,000USD448,000USD-138,000USD274,000USD
    End Cash Flow4,358,000USD———————
    Net Income—-278,000USD236,000USD-466,000USD-1,835,000USD4,495,000USD728,000USD1,313,000USD
    Other Non Cash Items—-4,631,000USD428,000USD301,000USD451,000USD258,000USD85,000USD218,000USD
    Total Cash From Operating Activities—-1,339,000USD-1,735,000USD600,000USD6,868,000USD490,000USD-283,000USD311,000USD
    Free Cash Flow—-1,376,000USD-1,977,000USD554,000USD6,615,000USD448,000USD-377,000USD311,000USD
    Total Cashflows From Investing Activities—-14,000USD-242,000USD-46,000USD-253,000USD-42,000USD-94,000USD—
    Net Borrowings—-39,000USD-39,000USD-38,000USD-38,000USD-38,000USD-37,000USD-37,000USD
    Total Cash From Financing Activities—-36,000USD168,000USD-14,000USD-32,000USD0USD239,000USD-37,000USD
    Begin Period Cash Flow—8,516,000USD10,325,000USD9,785,000USD3,202,000USD2,754,000USD2,892,000USD2,618,000USD
    End Period Cash Flow—7,127,000USD8,516,000USD10,325,000USD9,785,000USD3,202,000USD2,754,000USD2,892,000USD
    Other Cashflows From Investing Activities—23,000USD——————
    Other Cashflows From Financing Activities—-36,000USD—-14,000USD—38,000USD276,000USD-37,000USD
    Investments———-46,000USD-253,000USD-42,000USD-94,000USD0USD
    Sale Purchase Of Stock————0USD0USD0USD0USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-04-30 · USDFY 20252025-04-30 · USDFY 20242024-04-30 · USDFY 20232023-04-30 · USDFY 20222022-04-30 · USDFY 20212021-04-30 · USDFY 20202020-04-30 · USDFY 20192019-04-30 · USD
    Net Income-1,175,000USD4,701,000USD-7,276,000USD-5,335,000USD548,000USD334,000USD-1,975,000USD128,000USD
    Depreciation1,377,000USD1,640,000USD1,867,000USD2,246,000USD1,627,000USD1,184,000USD825,000USD606,000USD
    Stock Based Compensation1,237,000USD654,000USD1,118,000USD864,000USD912,000USD598,000USD600,000USD636,000USD
    Unclassified Operating Cash Flow-6,651,000USD——1,002,000USD————
    Change To Account Receivables-2,002,000USD-1,436,000USD-1,991,000USD1,308,000USD-2,818,000USD-2,265,000USD-670,000USD-531,000USD
    Change To Liabilities2,595,000USD——4,026,000USD5,972,000USD-805,000USD3,474,000USD582,000USD
    Change In Working Capital740,000USD-621,000USD-3,823,000USD4,226,000USD2,336,000USD-4,169,000USD2,492,000USD11,000USD
    Operating Cash Flow-4,472,000USD———————
    Capital Expenditures-564,000USD-389,000USD-836,000USD-2,872,000USD-2,384,000USD-3,281,000USD-2,220,000USD-834,000USD
    Unclassified Investing Cash Flow24,000USD——2,872,000USD2,384,000USD3,169,000USD2,108,000USD—
    Investing Cash Flow-540,000USD———————
    Net Debt Issuance-135,000USD———————
    Unclassified Financing Cash Flow234,000USD————-1,369,000USD-4,455,000USD-1,465,000USD
    Financing Cash Flow99,000USD———————
    Change In Cash-4,913,000USD7,167,000USD-7,500,000USD1,111,000USD4,320,000USD-3,655,000USD5,105,000USD2,231,000USD
    End Cash Flow4,872,000USD———————
    Other Non Cash Items—1,012,000USD1,977,000USD952,000USD1,074,000USD323,000USD403,000USD410,000USD
    Total Cash From Operating Activities—7,386,000USD-6,137,000USD3,955,000USD6,497,000USD-1,681,000USD2,905,000USD1,862,000USD
    Free Cash Flow—6,997,000USD-6,973,000USD1,083,000USD4,113,000USD-4,962,000USD685,000USD1,028,000USD
    Investments—-389,000USD-836,000USD-2,872,000USD-2,384,000USD-3,169,000USD-2,220,000USD-834,000USD
    Total Cashflows From Investing Activities—-389,000USD-836,000USD-2,872,000USD-2,384,000USD-3,169,000USD-2,220,000USD-834,000USD
    Net Borrowings—-150,000USD-146,000USD0USD0USD-174,000USD-35,000USD-262,000USD
    Total Cash From Financing Activities—170,000USD-527,000USD11,000USD207,000USD1,195,000USD4,420,000USD1,203,000USD
    Sale Purchase Of Stock—0USD-634,000USD-74,000USD207,000USD1,369,000USD4,455,000USD1,465,000USD
    Begin Period Cash Flow—2,618,000USD10,118,000USD9,007,000USD4,687,000USD8,342,000USD3,237,000USD1,006,000USD
    End Period Cash Flow—9,785,000USD2,618,000USD10,101,000USD9,007,000USD4,687,000USD8,342,000USD3,237,000USD
    Other Cashflows From Financing Activities—170,000USD253,000USD85,000USD207,000USD1,369,000USD4,455,000USD1,465,000USD
    Cash And Cash Equivalents Changes———1,111,000USD4,320,000USD-3,655,000USD5,105,000USD2,231,000USD
    Change To Inventory—————-1,099,000USD1,037,000USD571,000USD
    Other Cashflows From Investing Activities—————112,000USD112,000USD112,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q4 2026Quarterly · 2026-04-30ProductPharmacology Services13,204,000USDDisclosure
    Q4 2026Quarterly · 2026-04-30ProductProduct And Service Other336,000USDDisclosure
    Q4 2026Quarterly · 2026-04-30ProductTranslational Oncology Solutions TOSLicense Revenue296,000USDDisclosure
    FY 2026Yearly · 2026-04-30ProductPharmacology Services57,133,000USDDisclosure
    FY 2026Yearly · 2026-04-30ProductProduct And Service Other1,528,000USDDisclosure
    FY 2026Yearly · 2026-04-30ProductTranslational Oncology Solutions TOSLicense Revenue764,000USDDisclosure
    Q3 2026Quarterly · 2026-01-31ProductPharmacology Services16,184,000USD0001628280-26-017345
    Q3 2026Quarterly · 2026-01-31ProductProduct And Service Other375,000USD0001628280-26-017345
    Q3 2026Quarterly · 2026-01-31ProductTranslational Oncology Solutions TOSLicense Revenue0USD0001628280-26-017345
    Q2 2026Quarterly · 2025-10-31ProductPharmacology Services14,515,000USD0001628280-25-057082
    Q2 2026Quarterly · 2025-10-31ProductProduct And Service Other363,000USD0001628280-25-057082
    Q2 2026Quarterly · 2025-10-31ProductTranslational Oncology Solutions TOSLicense Revenue157,000USD0001628280-25-057082
    Q1 2026Quarterly · 2025-07-31ProductPharmacology Services13,230,000USD0000771856-25-000023
    Q1 2026Quarterly · 2025-07-31ProductProduct And Service Other454,000USD0000771856-25-000023
    Q1 2026Quarterly · 2025-07-31ProductTranslational Oncology Solutions TOSLicense Revenue311,000USD0000771856-25-000023
    Q4 2025Quarterly · 2025-04-30ProductPharmacology Services11,348,000USDDisclosure
    Q4 2025Quarterly · 2025-04-30ProductProduct And Service Other831,000USDDisclosure
    Q4 2025Quarterly · 2025-04-30ProductTranslational Oncology Solutions TOSLicense Revenue176,000USDDisclosure
    FY 2025Yearly · 2025-04-30ProductPharmacology Services48,585,000USDDisclosure
    FY 2025Yearly · 2025-04-30ProductProduct And Service Other3,683,000USDDisclosure
    FY 2025Yearly · 2025-04-30ProductTranslational Oncology Solutions TOSLicense Revenue4,676,000USDDisclosure
    Q3 2025Quarterly · 2025-01-31ProductPersonalized Oncology Services0USD0001628280-25-012941
    Q3 2025Quarterly · 2025-01-31ProductPharmacology Services11,670,000USD0001628280-25-012941
    Q3 2025Quarterly · 2025-01-31ProductProduct And Service Other869,000USD0001628280-25-012941
    Q3 2025Quarterly · 2025-01-31ProductTranslational Oncology Solutions TOSLicense Revenue4,500,000USD0001628280-25-012941
    Q2 2025Quarterly · 2024-10-31ProductPharmacology Services12,498,000USD0001628280-25-057082
    Q2 2025Quarterly · 2024-10-31ProductProduct And Service Other991,000USD0001628280-25-057082
    Q2 2025Quarterly · 2024-10-31ProductTranslational Oncology Solutions TOSLicense Revenue0USD0001628280-25-057082
    Q1 2025Quarterly · 2024-07-31ProductPharmacology Services13,069,000USD0000771856-25-000023
    Q1 2025Quarterly · 2024-07-31ProductProduct And Service Other992,000USD0000771856-25-000023
    Q1 2025Quarterly · 2024-07-31ProductTranslational Oncology Solutions TOSLicense Revenue0USD0000771856-25-000023
    FY 2024Yearly · 2024-04-30ProductLicense And Maintenance0USD0001628280-25-035765
    FY 2024Yearly · 2024-04-30ProductPersonalized Oncology Services18,000USD0001628280-25-035765
    FY 2024Yearly · 2024-04-30ProductPharmacology Services47,035,000USD0001628280-25-035765
    FY 2024Yearly · 2024-04-30ProductProduct And Service Other3,102,000USD0001628280-25-035765
    FY 2023Yearly · 2023-04-30ProductPersonalized Oncology Services116,000USD0001628280-24-032321
    FY 2023Yearly · 2023-04-30ProductPharmacology Services50,708,000USD0001628280-24-032321
    FY 2023Yearly · 2023-04-30ProductProduct And Service Other3,046,000USD0001628280-24-032321
    FY 2022Yearly · 2022-04-30ProductOther Services2,227,000USD0001628280-23-025464
    FY 2022Yearly · 2022-04-30ProductPersonalized Oncology Services49,000USD0001628280-23-025464
    FY 2022Yearly · 2022-04-30ProductPharmacology Services46,833,000USD0001628280-23-025464
    FY 2021Yearly · 2021-04-30ProductOther Services1,401,000USD0001628280-22-019309
    FY 2021Yearly · 2021-04-30ProductPersonalized Oncology Services166,000USD0001628280-22-019309
    FY 2021Yearly · 2021-04-30ProductPharmacology Services39,473,000USD0001628280-22-019309
    FY 2020Yearly · 2020-04-30ProductOther Services71,000USD0001628280-21-014464
    FY 2020Yearly · 2020-04-30ProductPersonalized Oncology Services790,000USD0001628280-21-014464
    FY 2020Yearly · 2020-04-30ProductPharmacology Services31,262,000USD0001628280-21-014464
    FY 2019Yearly · 2019-04-30ProductOther Services306,000USD0001628280-20-010734
    FY 2019Yearly · 2019-04-30ProductPersonalized Oncology Services1,277,000USD0001628280-20-010734
    FY 2019Yearly · 2019-04-30ProductPharmacology Services25,484,000USD0001628280-20-010734

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.